Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it ...

The World Health Organisation (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...

Shares of Gilead Sciences Inc. slipped 4.28% to $109.64 Friday, on what proved to be an all-around dismal trading session for ...

See the latest Gilead Sciences GILD stock price (NASDAQ: GILD), related news, valuation, dividends and more to help you make your investing decisions.

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. Bridgewater ...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or “ ...

WHO’s director general described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the absence of a vaccine.

Gilead Sciences Inc. closed 5.60% below its 52-week high of $119.96, which the company achieved on March 10th.

Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, ...